Skip to main content

Advertisement

SpringerLink
Log in

Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-019-0194-4

    Article  PubMed  Google Scholar 

  2. Yshii LM, Gebauer CM, Pignolet B et al (2016) CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain 139:2923–2934. https://doi.org/10.1093/brain/aww225

    Article  PubMed  Google Scholar 

  3. Vogrig A, Fouret M, Joubert B et al (2019) Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflammation 6:e604. https://doi.org/10.1212/NXI.0000000000000604

    Article  Google Scholar 

  4. Vogrig A, Gigli GL, Segatti S et al (2019) Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol. https://doi.org/10.1007/s00415-019-09544-1

    Article  PubMed  Google Scholar 

  5. Simard C, Vogrig A, Joubert B et al (2020) Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflammation. https://doi.org/10.1212/NXI.0000000000000699

    Article  Google Scholar 

  6. Vogrig A, Muñiz-Castrillo S, Joubert B et al (2020) Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-323055

    Article  PubMed  Google Scholar 

  7. Hottinger AF (2016) Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29:806–812. https://doi.org/10.1097/WCO.0000000000000391

    Article  CAS  PubMed  Google Scholar 

  8. Papadopoulos KP, Romero RS, Gonzalez G et al (2018) Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 23:118–120. https://doi.org/10.1634/theoncologist.2017-0344

    Article  PubMed  Google Scholar 

  9. Matsuoka H, Kimura H, Koba H et al (2018) Nivolumab-induced limbic encephalitis with anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer 19:e597–e599. https://doi.org/10.1016/j.cllc.2018.04.009

    Article  PubMed  Google Scholar 

  10. Raskin J, Masrori P, Cant A et al (2017) Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. Lung Cancer Amst Neth 109:74–77. https://doi.org/10.1016/j.lungcan.2017.05.002

    Article  Google Scholar 

Download references

Acknowledgements

We thank NeuroBioTec Hospices Civils de Lyon BRC (France, AC-2013-1867, NFS96-900) for banking sera and CSF samples.

Funding

This study is supported by research grants from ANR (ANR-14-CE15-0001-MECANO), and FRM (Fondation pour la recherche médicale, DQ20170336751). This work has been developed within the BETPSY project, which is supported by a public grant overseen by the French National Research Agency (ANR), as part of the second “Investissements d’Avenir” program (reference ANR-18-RHUS-0012). We thank Philip Robinson and Véréna Landel for their help in manuscript preparation (Direction de la Recherche Clinique, Hospices Civils de Lyon).

Author information

Authors and Affiliations

  1. French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Lyon, France

    Neus Mongay-Ochoa, Alberto Vogrig, Sergio Muñiz-Castrillo & Jerome Honnorat

  2. Synatac Team, Institute NeuroMyoGène, INSERM U1217/CNRS UMR5310, Université de Lyon, Université Claude Bernard, Lyon 1, Lyon, France

    Neus Mongay-Ochoa, Alberto Vogrig, Sergio Muñiz-Castrillo & Jerome Honnorat

  3. Department of Neurology, Hospital Universitari de Bellvitge, Barcelona, Spain

    Neus Mongay-Ochoa

Authors
  1. Neus Mongay-Ochoa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Vogrig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sergio Muñiz-Castrillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jerome Honnorat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jerome Honnorat.

Ethics declarations

Conflicts of interest

The authors have no conflicts of interest to disclose.

Ethical standards

All procedures were performed in accordance with the institutional ethics committee and the Declaration of Helsinki. Written consent was obtained from all patients.

Data access, responsibility, and analysis

The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Severe four-limb proprioceptive ataxia in a patient with anti-Hu sensory neuronopathy developing after treatment with pembrolizumab (MP4 19679 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mongay-Ochoa, N., Vogrig, A., Muñiz-Castrillo, S. et al. Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment. J Neurol 267, 2154–2156 (2020). https://doi.org/10.1007/s00415-020-09940-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-020-09940-y

Search

Navigation